StockIQpro
NASDAQ:CTXR

Citius Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Citius Pharmaceuticals, Inc. reported net income of −$39.7M in fiscal 2025. The diluted share count rose 64.5%.Summary generated from Citius Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Dec 23, 2025.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−57.8%
Debt / equity4.44
Free cash flown/a
FCF marginn/a
Share count change+64.5%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue00n/an/an/a
Operating income−24−33−37−42−39
Net income−23−34−33−39−40
Free cash flow−24n/an/an/an/a

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations